Mayzent Unió Europea - islandès - EMA (European Medicines Agency)

mayzent

novartis europharm limited  - siponimod fúmarsýru - heila-og mænusigg, köstum tilkynnt - valdar ónæmisbælandi lyf - mayzent er ætlað fyrir meðferð fullorðinn sjúklinga með efri framsækið heila-og mænusigg (spms) með virk sjúkdómur sést af köst eða hugsanlegur aðgerðir æsandi virkni.

Dimethyl fumarate Neuraxpharm Unió Europea - islandès - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Copaxone Stungulyf, lausn í áfylltri sprautu 20 mg/ml Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

copaxone stungulyf, lausn í áfylltri sprautu 20 mg/ml

teva gmbh - glatiramer acetat - stungulyf, lausn í áfylltri sprautu - 20 mg/ml

Nicorette Invisi Forðaplástur 10 mg/16 klst. Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

nicorette invisi forðaplástur 10 mg/16 klst.

mcneil denmark aps - nicotinum - forðaplástur - 10 mg/16 klst.

Nicorette Invisi Forðaplástur 15 mg/16 klst. Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

nicorette invisi forðaplástur 15 mg/16 klst.

mcneil denmark aps - nicotinum - forðaplástur - 15 mg/16 klst.

Nicorette Invisi Forðaplástur 25 mg/16 klst. Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

nicorette invisi forðaplástur 25 mg/16 klst.

mcneil denmark aps - nicotinum - forðaplástur - 25 mg/16 klst.

Remurel (Brabio 20 mg/ml Stungulyf, lausn í áfylltri sprautu) Stungulyf, lausn í áfylltri sprautu 20 mg/ml Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

remurel (brabio 20 mg/ml stungulyf, lausn í áfylltri sprautu) stungulyf, lausn í áfylltri sprautu 20 mg/ml

zentiva k.s.* - glatiramer acetat - stungulyf, lausn í áfylltri sprautu - 20 mg/ml

Sabrilex Filmuhúðuð tafla 500 mg Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

sabrilex filmuhúðuð tafla 500 mg

sanofi-aventis norge as - vigabatrinum inn - filmuhúðuð tafla - 500 mg

Advagraf Unió Europea - islandès - EMA (European Medicines Agency)

advagraf

astellas pharma europe bv - takrólímus - graft rejection - Ónæmisbælandi lyf - fyrirbyggja grætt höfnun í fullorðinn nýra eða lifur ígrædd nýru viðtakendur. meðferð við höfnun á fjölgildingu sem er ónæm fyrir meðferð með öðrum ónæmisbælandi lyfjum hjá fullorðnum sjúklingum.

Blincyto Unió Europea - islandès - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - forvarnarfrumuæxli-eitilfrumuhvítblæði - Æxlishemjandi lyf - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.